TABLE 1.
Baseline characteristics of study participants
| Placebo (n = 45) | 40 mg DRI (n = 48) | 60 mg DRI (n = 49) | |
|---|---|---|---|
| Age, y (mean ± SD) | 53.8 ± 5.1 | 52.2 ± 4.8 | 53.2 ± 5.6 |
| Postmenopause status, y (mean ± SD) | 5.6 ± 5.9 | 4.0 ± 4.9 | 5.8 ± 6.1 |
| BMI, kg/m2 | 27.4 ± 4.1 | 29.9 ± 6.1 | 28.3 ± 5.2 |
| Alcohol, drinks/wk | 1.7 ± 2.6 | 1.8 ± 3.2 | 1.7 ± 2.7 |
| Hot flash severity | 2.1 ± 0.6 | 2.2 ± 0.6 | 2.1 ± 0.6 |
| Hot flash frequency | 7.3 ± 2.5 | 8.5 ± 3.5 | 7.6 ± 2.6 |
| Hot flash score | 15.9 ± 8.4 | 20.2 ± 12.2 | 16.3 ± 8.0 |
| Race, % | |||
| White | 66 | 60 | 60 |
| African-American | 24 | 36 | 30 |
| Other | 10 | 4 | 10 |
| Education, % | |||
| Postgraduate | 28 | 25 | 28 |
| College | 53 | 56 | 59 |
| High school | 19 | 19 | 13 |
| Smokers (n) | 11 | 9 | 6 |
Values are means ± SD. There was no significant difference among the three groups at baseline.
DRI, daidzein-rich isoflavone aglycone; BMI, body mass index.